United States Biotechnology & Medical Research

Arrivent Biopharma Inc (AVBP)

Arrivent Biopharma Inc has seen no insider trading activity within the past ninety days. The most recent recorded transaction occurred on December 10, 2025, involving a significant sale of shares by Hillhouse Investment Management, Ltd. Prior to this, multiple entities executed purchase orders throughout January 2024.
Ticker: AVBP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Arrivent Biopharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.5
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
258.54
Quantity 63,795 -9.9%
Value US$4,094,982
1.5
GORDON CARL L Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 222,222 +17.2%
Value US$3,999,996
2.9
HEALY JAMES Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 444,444 +35.5%
Value US$7,999,992
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 222,222 +17.2%
Value US$3,999,996
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 222,222 +17.2%
Value US$3,999,996
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-03 2025-12-10 S Sale
1.6
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Large shareholder
40,435 +24.5%
449.36
US$1,011,716 		40,435 +24.5% 449.36 US$1,011,716
2024-02-01 2024-01-30 B Purchase
1.6
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Large shareholder
20,100 +33.1%
320.22
US$4,848,610 		20,100 +33.1% 320.22 US$4,848,610
2024-01-31 2024-01-30 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
63,795 -9.9%
258.54
US$4,094,982 		63,795 -9.9% 258.54 US$4,094,982
2024-01-31 2024-01-30 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
222,222 +17.2%
18.00
US$3,999,996 		222,222 +17.2% 18.00 US$3,999,996
2024-01-31 2024-01-30 B Purchase
2.9
HEALY JAMES
Non-Executive Director
444,444 +35.5%
18.00
US$7,999,992 		444,444 +35.5% 18.00 US$7,999,992
2024-01-31 2024-01-30 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
222,222 +17.2%
18.00
US$3,999,996 		222,222 +17.2% 18.00 US$3,999,996
2024-01-31 2024-01-30 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
222,222 +17.2%
18.00
US$3,999,996 		222,222 +17.2% 18.00 US$3,999,996
Explore more

More insider trading research around Arrivent Biopharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America